Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients?

Kao CH, Sun LM, Chen PC, Lin MC, Liang JA, Muo CH, Chang SN, Sung FC.

Ann Oncol. 2013 Feb;24(2):523-30. doi: 10.1093/annonc/mds472. Epub 2012 Oct 30.

PMID:
23110810
2.

Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.

Chiu CC, Huang CC, Chen YC, Chen TJ, Liang Y, Lin SJ, Chen JW, Leu HB, Chan WL.

Intern Med. 2013;52(9):939-46. Epub 2012 Mar 1.

3.

Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.

Lin HC, Hsu YT, Kachingwe BH, Hsu CY, Uang YS, Wang LH.

J Clin Pharm Ther. 2014 Aug;39(4):354-60. doi: 10.1111/jcpt.12151. Epub 2014 Mar 24.

PMID:
24661226
4.

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.

Koro C, Barrett S, Qizilbash N.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):485-92.

PMID:
17192841
5.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
6.

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.

Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA.

Hepatology. 2012 May;55(5):1462-72. doi: 10.1002/hep.25509.

PMID:
22135104
7.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
8.

The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure.

Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A.

J Am Coll Cardiol. 2007 Jul 3;50(1):32-6. Epub 2007 Jun 18.

9.

Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan.

Liao KF, Lai SW, Li CI, Chen WC.

J Gastroenterol Hepatol. 2012 Apr;27(4):709-13. doi: 10.1111/j.1440-1746.2011.06938.x.

PMID:
21929650
10.

Use of thiazolidinediones and risk of bladder cancer: disease or drugs?

Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML.

Curr Drug Saf. 2013 Nov;8(5):364-70.

PMID:
24215315
11.
12.

Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of thiazolidinediones for diabetes.

Wen YW, Huang WF, Lee YC, Kuo KN, Tsai CR, Tsai YW.

BMC Health Serv Res. 2011 Jan 31;11:21. doi: 10.1186/1472-6963-11-21.

13.

Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study.

Chen SW, Tsan YT, Chen JD, Hsieh HI, Lee CH, Lin HH, Wang JD, Chen PC; Health Data Analysis in Taiwan Research Group.

Diabetes Care. 2013 Feb;36(2):369-75. doi: 10.2337/dc11-2197. Epub 2012 Oct 5.

14.

Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes.

Chao TF, Leu HB, Huang CC, Chen JW, Chan WL, Lin SJ, Chen SA.

Int J Cardiol. 2012 Apr 19;156(2):199-202. doi: 10.1016/j.ijcard.2011.08.081. Epub 2011 Sep 17.

PMID:
21930315
15.
16.

Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan.

Chen YL, Cheng KC, Lai SW, Tsai IJ, Lin CC, Sung FC, Lin CC, Chen PC.

Gastric Cancer. 2013 Jul;16(3):389-96. doi: 10.1007/s10120-012-0197-7. Epub 2012 Oct 5.

PMID:
23053824
17.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
18.

The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan.

Huang MY, Chung CH, Chang WK, Lin CS, Chen KW, Hsieh TY, Chien WC, Lin HH.

Am J Cancer Res. 2017 Jul 1;7(7):1606-1616. eCollection 2017.

19.

Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.

Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST.

Am J Gastroenterol. 2013 Apr;108(4):510-9; quiz 520. doi: 10.1038/ajg.2013.7. Epub 2013 Feb 12. Review.

PMID:
23399556
20.

Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

Bazelier MT, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, Vestergaard P, de Vries F.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):507-14. doi: 10.1002/pds.3234. Epub 2012 Mar 6.

PMID:
22392882

Supplemental Content

Support Center